Psychedelic therapy is moving closer to mainstream mental health care. A new White House executive order accelerates pathways for psychedelic treatments, while late-stage drug development advances for compounds such as psilocybin and ibogaine. For licensed psychotherapists, this creates a pressing set of questions:

• What is actually changing right now?
• What could FDA approval mean for my psychotherapy practice, my referrals, my documentation, and my scope of practice?
• How should I respond when patients ask about psychedelic therapy and whether it might help them?  

This timely webinar is designed for licensed psychotherapists who want a clear, grounded update on the FDA approval timeline for psychedelic therapies and a practical framework for preparing now.

We’ll break down:

• What the recent executive order does and does not mean for psychedelic treatment access
• Where the FDA timeline stands for MDMA, psilocybin, ibogaine, and related therapies
• What eventual FDA approval may mean for psychotherapy practices, including clinical roles, collaboration, referrals, preparation, and ethical boundaries
• How to talk with patients about psychedelic therapies today with nuance, accuracy, and confidence
• What therapists can do now to prepare--without stepping outside their current scope of practice  

If your patients are already asking about psychedelic therapy, this conversation will help you answer with more clarity and less guesswork. You’ll leave with a realistic picture of what may be coming, what remains uncertain, and how to position your practice wisely in a rapidly changing field.